CompoAtlas

GinkoPrim® Max 100 mg (Paziņots 2011.)

Food supplement registered in Latvia

Register snapshot dated 2 May 2025. It does not establish the current status of the product.

Number published by PVD
0000179/2012
Type
Food supplement
Published status
Status not provided in this export; the validity date is shown separately
Licence holder
Walmark, SIA
Manufacturer
Walmark,a.s.
Origin
Latvija
Register snapshot
2 May 2025
Recommended daily intake (Latvian text)
1 tablete dienā pēc ēšanas, uzdzerot ūdeni
Published pack size
tabletes pa 950 mg
Published packaging
30, 60 vai 90 tabletes iepakojumā

This registration does not constitute authorisation for sale in France or the European Union. It does not demonstrate the safety or efficacy of the product.

The foreign register category does not determine the regulatory category of the product in France.

Published composition

Published namePublished text and quantityRecognised ingredientRole or context
Magnijsminerals ; Magnijs ; 150 ; mgMagnésiumVitamin or mineral
Divdaivu ginka lapu standartizēts ekstrakts (satur flavonglikozīdus 24%, terpenolaktonus 6%)plants ; Divdaivu ginka lapu standartizēts ekstrakts (satur flavonglikozīdus 24%, terpenolaktonus 6%) ; Ginkgo biloba ; 100 ; mgginkgo bilobaPlant
Mikrokristāliskā celuloze (E460)otherIngredients ; Mikrokristāliskā celuloze (E460)Listed as food additive E 460(i) (EU Union list)Role not identified
Hidroksipropilmetilceluloze (E464)otherIngredients ; Hidroksipropilmetilceluloze (E464)Listed as food additive E 464 (EU Union list)Role not identified
Glicerīns (E422)otherIngredients ; Glicerīns (E422)Listed as food additive E 422 (EU Union list)Role not identified
Titāna dioksīds (E171)otherIngredients ; Titāna dioksīds (E171)Not recognisedRole not identified
Riboflavīns (E101)otherIngredients ; Riboflavīns (E101)Vitamine B2 (riboflavine)Vitamin or mineral
Indigokarmīns (E132)otherIngredients ; Indigokarmīns (E132)Listed as food additive E 132 (EU Union list)Role not identified
Briljantzilais FCF (E133)otherIngredients ; Briljantzilais FCF (E133)Listed as food additive E 133 (EU Union list)Role not identified
Saflora koncentrātsotherIngredients ; Saflora koncentrātsNot recognisedRole not identified
Taukskābju magnija sāļi (E470b)otherIngredients ; Taukskābju magnija sāļi (E470b)Listed as food additive E 470b (EU Union list)Role not identified
Triglicerīdu eļļaotherIngredients ; Triglicerīdu eļļaNot recognisedRole not identified

Quantities are reproduced as published. The export does not specify their basis: the recommended daily intake cannot be used to calculate a daily dose. No daily dose is estimated. Latvian names are retained without translation.

Manufacturer countries

Čehija

French and European references for recognised ingredients

Unrecognised ingredients are not assessed. The absence of a signal does not establish product compliance.

Official source

View the official register

Official PVD export

Internet Archive copy dated 3 May 2025

PVD, food supplement register, CC0 1.0. Quantities and the date of each snapshot are retained as published.

CC0 1.0

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Divdaivu ginka lapu standartizēts ekstrakts (satur flavonglikozīdus 24%, terpenolaktonus 6%)
    Read the warning, when it applies and the studies cited

    GINKGO - GINKGO BILOBA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    Sources cited by Health Canada (3)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Newton (MA): Integrative Medicine Communications; 2000.
    • WHO 1999: World Health Organization. WHO monographs on selected medicinal plants, Volume 1. Geneva (CHE): World Health Organization; 1999.
    • OMS 1999 : Organisation mondiale de la santé (OMS). Monographs on selected medicinal plants, Volume 1. Genève (CHE): Organisation mondiale de la santé; 1999.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    Sources cited by Health Canada (1)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Contraindications

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    Sources cited by Health Canada (1)
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    Sources cited by Health Canada (3)
    • Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with ginkgo biloba: a case report and systematic review of the literature. Journal of General Internal Medicine 2005;20(7):657-661. PubMed Systematic review
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. Second Edition. Boca Raton (FL): Taylor and Francis Group; 2013.

    Health Canada monograph dated 25 July 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

The evidence date of this ingredient list is unknown.

Has the product changed? Photograph the packaging.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “GinkoPrim® Max 100 mg (Paziņots 2011.)”, https://compoatlas.com/en/supplements/latvia/3458-ginkoprim-max-100-mg-pazinots-2011, updated 28 October 2026.

Enter to analyse, Shift+Enter for a new line